The Biodefense Diplomacy Enhancement Act directs the Secretary of State to advance U.S. foreign policy goals by strengthening diplomatic engagement on biotechnology, biosecurity, and biodefense with NATO, major non‑NATO allies, and other partners. It requires two named strategies — a NATO Biodefense Strategy and an International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy — and asks the State Department to assess gaps, recommend capability development, and explore export‑control coordination.
This is a procedural bill with immediate agency obligations rather than new criminal penalties or regulatory regimes. For practitioners it matters because it formalizes diplomatic leadership on dual‑use biotechnology issues, creates deadlines for an unclassified report (with a classified annex option), and pushes export control and research‑security conversations into NATO and allied policy fora — potentially changing how export controls and international research partnerships are negotiated and funded.
At a Glance
What It Does
The bill requires the Secretary of State to pursue enhanced biodefense cooperation with NATO and other allies, produce a NATO Biodefense Strategy and an International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy, and submit them in a report to Congress. It directs the State Department to identify capability gaps, assess export‑control coordination (including with existing regimes), and recommend uses of Department of State NADR programs and funds.
Who It Affects
Directly affects the State Department’s Bureau of Arms Control and related diplomatic posts (including the U.S. Mission to NATO), NATO planning and defense planners, and allied export‑control authorities. Indirectly affects federal partners (DoD, HHS, Commerce), laboratories and biotechnology firms engaged in international work, and recipients of NADR‑funded programs.
Why It Matters
The bill institutionalizes diplomatic ownership of biosecurity policy within U.S. foreign policy, pushing routine discussion of dual‑use biotech into alliance settings. That can shift where export‑control decisions and research‑security norms are negotiated, and it signals to partners that the U.S. will prioritize interoperability, attribution, and resilience in biological incidents.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill assigns the Secretary of State primary responsibility for advancing U.S. diplomatic efforts on biotechnology, biosecurity, and biodefense, and it contemplates delegation to the Under Secretary for Arms Control and International Security. It instructs that work be coordinated with the Under Secretary for Political Affairs and the U.S. Permanent Representative to NATO, and it lists specific NATO‑focused activities such as advocating for policy development, strengthening interoperability, and evaluating NATO’s CBRN policy for potential revisions.
The thrust is to push biodefense onto alliance planning tracks rather than treating it solely as a domestic public‑health or defense technical issue.
Beyond NATO, the State Department must pursue cooperation with both NATO members and major non‑NATO allies. That includes exploring cooperative commitments, coordinating export‑control policy approaches for dual‑use biotechnology items, promoting uniform safety and security standards in research, and helping enforce the Biological Weapons Convention.
The bill explicitly ties diplomatic activity to capability development and recommends leveraging Department of State nonproliferation and NADR authorities and funds to expand partner capacity.The bill requires two named strategies with concrete content: the NATO Biodefense Strategy must assess current cooperation, identify planning and deployment gaps, and recommend fixes; the International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy must propose bilateral and multilateral commitments, evaluate coordinating export controls in addition to regimes like the Wassenaar Arrangement and Australia Group, and outline NADR program uses. Both strategies are limited to biological agents and toxins as defined in 18 U.S.C. §178.For congressional oversight the State Department must deliver the strategies in a report within 270 days of enactment in unclassified form (with an optional classified annex).
The Under Secretary for Arms Control and International Security must also brief the designated congressional committees within 90 days after enactment in response to significant developments tied to the report or other material biosecurity developments. The bill is procedural: it orders assessments, strategy development, coordination, and reporting rather than imposing new licensing regimes, criminal penalties, or regulatory standards on private actors.
The Five Things You Need to Know
The bill requires two named strategies: a NATO Biodefense Strategy and an International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy that assess gaps and make actionable recommendations.
The State Department must submit the strategies to Congress in an unclassified report (with an optional classified annex) within 270 days of enactment.
The Under Secretary for Arms Control and International Security must brief the House Foreign Affairs and Senate Foreign Relations Committees within 90 days after enactment in response to significant developments tied to the report or other global biosecurity developments.
The strategies are expressly limited to biological agents and toxins as defined in 18 U.S.C. §178, narrowing the statutory scope to those materials.
The bill directs assessment of export‑control coordination beyond existing regimes (Wassenaar Arrangement, Australia Group), and asks the State Department to identify how NADR programs and funds could be used to expand partner capabilities.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s citation as the “Biodefense Diplomacy Enhancement Act.” This is a standard drafting device but signals the bill’s diplomatic and defense orientation for subsequent implementation guidance and interagency planning.
Overall diplomatic mandate
Directs the Secretary of State to advance U.S. foreign‑policy goals by improving cooperation on biodefense, biosecurity, and biotechnology with allies and partners. Practically, this creates a standing diplomatic brief and a formal ownership claim within the State Department to lead on these topics in international fora rather than delegating them wholly to health or defense agencies.
NATO engagement and priorities
Requires the State Department (via the Under Secretary for Arms Control if delegated) to pursue enhanced biodefense cooperation within NATO, including advocating for NATO policy development, evaluating interoperability gaps, and exploring amendments to NATO’s CBRN Defence Policy. This provision pushes biodefense into NATO planning cycles and could trigger joint exercises, NATO‑level requirements for member states, and new capability development discussions.
Bilateral and partner cooperation, export control coordination
Directs diplomatic engagement with NATO members and major non‑NATO allies to explore cooperative commitments on biotechnology and biosecurity, coordinate export‑control policy on dual‑use biotech items, promote research safety standards, and collaborate on enforcing the Biological Weapons Convention. For implementers this provision opens a diplomatic channel to harmonize export‑control stances and push for common research‑security norms among willing partners.
Required strategies and assessments
Mandates two explicit strategies: a NATO Biodefense Strategy and an International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy. Each must assess current cooperation, identify planning and capability gaps, recommend how to address those gaps, evaluate feasibility of export‑control coordination (including consideration of existing regimes), and outline use of NADR and related funds to build partner capacity. The text ties recommendations to practical tools — capability development, coordination mechanisms, and funding pathways — making the strategies implementation‑oriented rather than purely declaratory.
Reporting to Congress
Requires submission of the strategies to the House Foreign Affairs and Senate Foreign Relations Committees within 270 days in unclassified form, with an optional classified annex. That timeline creates a near‑term deliverable and obligates the State Department to translate interagency work into a report usable by Congress and oversight staff.
Congressional briefing requirement and definitions
Requires the Under Secretary for Arms Control to brief the designated committees within 90 days after enactment on significant developments tied to the report and other material global biosecurity developments, and includes statutory definitions for terms like biodefense, biosecurity, biosurveillance, biotechnology, and ‘‘major non‑NATO allies.’u These definitions narrow interpretive disputes but also anchor the strategies to the statutory language of 18 U.S.C. §178 for biological agents and toxins.
This bill is one of many.
Codify tracks hundreds of bills on Foreign Affairs across all five countries.
Explore Foreign Affairs in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. State Department policymakers and Arms Control bureau staff — gains a clear diplomatic mandate, budget‑priority justification, and a deliverable to coordinate interagency and alliance activity on biosecurity. This strengthens their leverage in international fora.
- NATO defense and planning offices — receives a U.S. push to prioritize biodefense in alliance planning, which can accelerate interoperability projects, joint exercises, and capability development funding among member states.
- Allied public‑health and biosecurity agencies in partner countries — stands to benefit from coordinated NADR‑style funding recommendations, capacity‑building proposals, and shared standards that improve biosurveillance and emergency response interoperability.
- Export‑control and nonproliferation practitioners — the bill institutionalizes a diplomatic pathway to harmonize export controls and enforcement, creating more forum options to negotiate controls on dual‑use biotech items.
- Civil‑military biodefense planners — will receive clearer alliance guidance and recommended capability development priorities that can be integrated into national procurement and readiness plans.
Who Bears the Cost
- U.S. Department of State — must marshal staff time, interagency coordination, and probably incremental funding to produce the two strategies, run diplomatic outreach, and prepare the report and briefings within the statutory timelines.
- Other federal agencies (DoD, HHS, Commerce, DHS) — will be asked to provide technical inputs, participate in coordination, and potentially redirect limited technical staff to diplomatic support functions.
- NATO member states and partner governments — may face political and budgetary pressure to align standards, fund interoperability projects, or accept tighter export‑control cooperation, all of which impose programmatic costs.
- Biotech research institutions and companies engaged in international collaboration — could see increased compliance expectations or tighter export‑control scrutiny as allied policies converge, raising administrative and transactional costs.
- State Department NADR and foreign‑assistance accounts — could be called upon to reallocate or increase NADR resources to implement capacity‑building recommendations, potentially displacing other priorities.
Key Issues
The Core Tension
The central dilemma is balancing security and alliance coherence against the need to preserve open international scientific collaboration: the bill seeks to harden alliances and export controls to reduce bio‑risk, but tighter diplomatic coordination and controls can impede legitimate research, slow innovation, and complicate humanitarian or public‑health cooperation — a trade‑off with no technical fix, only policy choices about where to draw the line.
The bill is intentionally procedural: it orders assessments, strategy development, diplomatic coordination, and reporting rather than creating new regulatory authorities or criminal penalties. That makes implementation dependent on the State Department’s access to subject‑matter experts, interagency cooperation, and funding; without allocated resources the strategies may be aspirational rather than operational.
The statutory limitation to biological agents and toxins as defined in 18 U.S.C. §178 narrows the legal purview but may not capture platform‑level or tool‑level dual‑use risks (for example, general‑purpose gene‑editing capabilities or AI tools for sequence design) that are central to contemporary biosecurity debates.
Pushing export‑control coordination into NATO and allied diplomatic channels raises familiar trade‑offs: harmonized controls can reduce proliferation risk and simplify enforcement, but they also risk fragmenting global research collaboration and slowing benign scientific exchange. The bill encourages use of NADR funds to build partner capacity, but how those funds are prioritized and measured is left to executive branch implementation — raising questions about oversight, metrics of effectiveness, and potential opportunity costs for other nonproliferation work.
Finally, the option to submit a classified annex is sensible for sensitive capabilities, but using classified reporting for the most consequential assessments may constrain Congress’s ability to publicly evaluate the strategy or to use legislative levers to adjust funding or authorities promptly.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.